SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state
- 25 June 2025
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5776-5784
Abstract
Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.Keywords
Funding Information
- AstraZeneca
- AbbVie
This publication has 42 references indexed in Scilit:
- Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS studyThe Lancet Rheumatology, 2022
- Prevalence, Predictors, and Prognostic Benefits of Remission Achievement in Patients With Systemic Lupus Erythematosus: A Systematic ReviewArthritis Care & Research, 2020
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosusArthritis & Rheumatism, 2012
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusNew England Journal of Medicine, 2005
- Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialThe Lancet, 2004
- A study of the reliability of health state valuations in the Japanese EuroQol instrumentEnvironmental Health and Preventive Medicine, 2001
- Translation, Adaptation, and Validation of the SF-36 Health Survey for Use in JapanJournal of Clinical Epidemiology, 1998
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosusArthritis & Rheumatism, 1996
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990